B of A Securities Rates Definitive Healthcare (DH) sell

B of A Securities sets a new price target of $0.70 for Definitive Healthcare, downgrading it to 'sell', a 15.76% downside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 3:02 AM EDT · Updated Jul 1, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B of A Securities rated Definitive Healthcare Corp. ($DH) "sell" with a $0.70 price target on June 29, 2026.

Since the rating, $DH is up 19.4% after 1 week, up 1.4% after 1 month and up 38.9% to date (from the $0.72 close on Jun 29, 2026).

DH Definitive Healthcare Corp.

$1 -57.98% year to date

Daily close · Oct 16, 2026

Key Points

B of A Securities downgraded Definitive Healthcare Corp. to 'sell' on June 29, 2026, with a new price target of $0.70.
B of A Securities's $0.70 price target implies 15.76% downside from Definitive Healthcare Corp.'s ($DH) current $0.83 share price.
Shares of DH traded near $0.72 on Wednesday, with a market cap of approximately $88.7 million and a forward P/E of 4.5.
Recent insider activity included purchases by several executives and sales by the CEO and CFO in early June 2026.

Get $DH trade alerts by text

We text you when insiders, Congress or big funds trade $DH. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Definitive Healthcare Corp. alert may contain errors. Disclosures

On June 29, 2026, B of A Securities downgraded Definitive Healthcare Corp. (NasdaqGS: DH) to a 'sell' rating, setting a new price target of $0.70. This change reflects a cautious outlook on the company's future performance.

Analyst rating track record

B of A Securities vs. the S&P 500

YTD return +6.42% hypothetical

All-time return +30.32% S&P 500 +26.61%

vs. S&P 500 +3.71% ahead of the index

Hypothetical returns from B of A Securities's disclosed trades, not real profit or advice. How we model this.

Definitive Healthcare Corp. Stock Down 13.4%

Shares of NasdaqGS:DH traded near $0.72 on Wednesday. The company has a market cap of about $88.7 million, with a forward P/E ratio of 4.5 and a beta of 1.328. The stock's 52-week range has been between $0.62 and $4.70, with a 50-day moving average of $0.89 and a 200-day moving average of $1.98. Definitive Healthcare's balance sheet shows a current ratio of 1.75 and a quick ratio of 1.55, with a debt-to-equity ratio of 89.06.

12-month forecast

$DH price target

Definitive Healthcare Corp. daily closes and this analyst's $0.70 target. Not advice.

Recent Earnings

Definitive Healthcare reported revenues of approximately $238.3 million, though revenue growth has been negative at -5.5%. The company's net margin is -71.5%, and it has a return on equity of -75.5%. The next earnings release is expected on August 6, 2026.

Insider Buying and Selling at Definitive Healthcare Corp.

In early June 2026, several insiders were active in trading shares of Definitive Healthcare. On June 4, Samuel Hamood, Kathleen Winters, Scott Stephenson, and Sastry Chilukuri each bought 189,190 shares. On June 1, CEO Kevin Coop sold 66,050 shares at an average price of $0.99, and CFO Casey Heller sold 164,377 shares at the same price.

Analysts Set New Price Targets

On June 29, 2026, B of A Securities downgraded Definitive Healthcare to 'sell' with a target of $0.70. Barclays maintained its 'sell' rating with a target of $1.00 on March 30, 2026, while Canaccord Genuity maintained a 'hold' with a $3.00 target on February 27, 2026. The consensus among analysts is a 'buy' recommendation, with a mean target price of $2.20 based on six analyst opinions.

About Definitive Healthcare Corp.

Definitive Healthcare Corp., headquartered in Framingham, Massachusetts, provides a software-as-a-service platform offering healthcare commercial intelligence. The platform helps clients in sectors like biopharmaceuticals and medical devices manage sales, marketing, and product development. Founded in 2011, the company is led by CEO Kevin D. Coop and employs 678 people.

Bottom Line

B of A Securities' downgrade of Definitive Healthcare reflects a more cautious view of the company's prospects. With shares trading near the lower end of their 52-week range, investors will be watching upcoming earnings closely. As a reminder, analyst ratings and targets are based on expectations and may not reflect the company's current situation.